Back

Effect of glucagon-like peptide-1 receptor agonists on nonfatal cardiovascular events in patients with type 2 diabetes and high cardiovascular risk

31 August 2026 (11:15 - 12:00)
Organised by: Logo
Congress Presentation Part of: Therapeutic advancements in type 2 diabetes mellitus Antidiabetic Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Kenney Abraham

Staten Island University Hospital, Staten Island (United States of America)

3 More presentations in this session

Presentation thumbnail
Utilization patterns of potent GLP-1-RA among patients with type 2 diabetes in clinical practice
Ms S. Matseyko (DE)
Abstract
Presentation thumbnail
Characterization of cardiovascular risk profile and therapeutic management in patients with type 2 diabetes mellitus: insight from the CardioMET Italian registry
Doctor F. Marzano (Naples, IT)
Abstract
Presentation thumbnail
Cardiovascular effects of tirzepatide in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials
Professor M. Saffi (Porto Alegre, BR)
Abstract

Access the full session

Session thumbnail
Therapeutic advancements in type 2 diabetes mellitus

The Event

Event poster

ESC Congress 2026

31 August 2026 11:15 CET
You may be interested in
thumbnail
Congress Presentation
GLP-1-ra and heart failure-related outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis.
23 May 2023
thumbnail
Congress Presentation
Sodium-glucose cotransporter-2 inhibitors and their combination with glucagon like peptide-1 receptor agonists improve endothelial glycocalyx and arterial stiffness in type-2 diabetes
28 August 2020
thumbnail
Congress Presentation
GLP-1 receptor agonists as an opportunity for patients with atherosclerotic cardiovascular disease as well as obesity in Germany
1 September 2025
thumbnail
Congress Presentation
Effects of once-weekly semaglutide on coronary outcomes in patients with type 2 diabetes mellitus with or at high risk for cardiovascular disease: insights from the SUSTAIN-6 trial
7 April 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources